Description
A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively); inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively) as well as additional receptor tyrosine kinases; inhibits VEGF-induced upregulation of ICAM-1 and VCAM-1 and inhibits adhesion of multiple myeloma cells to HUVECs and proliferation of multiple myeloma cells; reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model at 30 and 100 mg/kg
Formal name: 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide
Synonyms: GSK-VEG10003|GW786034B
Molecular weight: 437.5
CAS: 444731-52-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cell Biology|Cell Signaling|Growth Factor Receptors||Research Area|Cell Biology|ECM & Adhesion Molecules